NASDAQ:AUTL

Autolus Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy AUTL

*Your capital is at risk

$1.62

-0.130 (-7.43%)

At Close: Jun 03, 2026

Autolus Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 10.82M and sold 0 AUTL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	10.82M shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 18, 2026 Buy	Restricted Share Units	Mcilvenny Patrick Paul SVP Finance	Officer	33 000 Value: $47.9K
Mar 18, 2026 Buy	Share Option (right to buy)	Dolski Robert Chief Financial Officer	C-Suite Officer	500 000 Value: $1.25M
Mar 18, 2026 Buy	Share Option (right to buy)	Dolski Robert Chief Financial Officer	C-Suite Officer	250 000 Value: $577.5K
Mar 18, 2026 Buy	Share Option (right to buy)	Dolski Robert Chief Financial Officer	C-Suite Officer	300 000 Value: $567.0K
Mar 18, 2026 Buy	Share Option (right to buy)	Dolski Robert Chief Financial Officer	C-Suite Officer	375 000 Value: $547.5K
Mar 18, 2026 Buy	Restricted Share Units	Dolski Robert Chief Financial Officer	C-Suite Officer	83 300 Value: $120.8K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	31 397 Value: $533.7K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	25 000 Value: $756.0K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	12 500 Value: $165.6K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	12 500 Value: $94.6K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	20 000 Value: $56.8K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	105 000 Value: $249.9K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	80 000 Value: $278.4K
Mar 18, 2026 Buy	Share Option (right to buy)	Bain Linda Director	Director	80 000 Value: $185.6K
Mar 18, 2026 Buy	Share Option (right to buy)	Iannone Robert Director	Director	105 000 Value: $249.9K
Mar 18, 2026 Buy	Share Option (right to buy)	Iannone Robert Director	Director	80 000 Value: $278.4K
Mar 18, 2026 Buy	Share Option (right to buy)	Iannone Robert Director	Director	80 000 Value: $185.6K
Mar 18, 2026 Buy	Ordinary Shares	Berriman John E Director	Director	0 Value: $0
Mar 18, 2026 Buy	Share Option (right to buy)	Berriman John E Director	Director	15 698 Value: $131.5K
Mar 18, 2026 Buy	Share Option (right to buy)	Berriman John E Director	Director	25 000 Value: $756.0K
Mar 18, 2026 Buy	Share Option (right to buy)	Berriman John E Director	Director	12 500 Value: $165.6K
Mar 18, 2026 Buy	Share Option (right to buy)	Berriman John E Director	Director	12 500 Value: $94.6K
Mar 18, 2026 Buy	Share Option (right to buy)	Berriman John E Director	Director	20 000 Value: $56.8K
Mar 18, 2026 Buy	Share Option (right to buy)	Berriman John E Director	Director	105 000 Value: $249.9K
Mar 18, 2026 Buy	Share Option (right to buy)	Berriman John E Director	Director	80 000 Value: $278.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AUTOLUS THERAPEUTICS PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a program...

Read Full Profile Here